- Home
- About
- About NephU
- Meet The Team
- Supporting Organizations
- Community Advisors
- Contact Us
- Diversity, Equity, & Inclusion
- IgAN
- Events
- Resource Center
- Rare Kidney Diseases (PKD, IgAN, & Others)
- Kidney Disease & Mental Health
- Kidney Disease & Comorbid Conditions
- Transplantation & Dialysis
- NephU Nutrition & The NephChefR
- Radiology Toolkit
- On Demand Webinars
- Infographics
- Podcasts
- Videos
- Request a Presentation
- Simulators
What interests you?+Help Us Enhance Your NephU ExperienceHelp Us Enhance Your NephU Experience
User experience form
Archives
Increasing Awareness Of Autosomal Dominant Polycystic Kidney Disease (ADPKD) In Underrepresented & Underserved Communities
About This Event
Increasing Awareness Of Autosomal Dominant Polycystic Kidney Disease (ADPKD) In Underrepresented & Underserved Communities
This presentation focuses on the impact of kidney disease and autosomal dominant polycystic kidney disease (ADPKD) in Black and Hispanic/Latino communities and the effects of social determinants of health on patients living with kidney. Diagnosing and managing the care of patients living with ADPKD will also be discussed.
Location
Fleming’s Prime Steakhouse & Wine Bar San Antonio
Featured Speakers
Biruh T Workeneh, MD, FASN
Associate Professor, Department of Emergency Medicine, Division of Internal MedicineThe University of Texas MD Anderson Cancer Center*
Dr Biruh Workeneh is a provider in the MD Anderson Internal Medicine Center and an Associate Professor in the Section of Nephrology. He is board-certified in Internal Medicine and joined MD Anderson in 2015.
Molly Jansen, PhD
Nephrology Senior Medical Science LiaisonOtsuka Pharmaceutical Development & Commercialization, Inc.*
Dr Molly Jansen is a Nephrology Medical Science Liaison at Otsuka Pharmaceutical Development & Commercialization, Inc. covering South Texas. Molly earned her Doctor of Philosophy degree in Biomedical Science from Wake Forest School of Medicine located in Winston-Salem, NC. While in graduate school, Molly worked as a Business Development Intern at Wake Forest Innovations, fostering the collaborative innovation between industry and the faculty and staff of Wake Forest Baptist Medical Center. After graduate school, Molly did a brief Medical Writing Fellowship with Impact Pharmaceutical Services. Prior to joining Otsuka, Molly worked at Reata Pharmaceuticals, Inc. where she helped to oversee the conduct of clinical trials across a variety of therapeutic areas including nephrology, neurology, and pulmonary, which is where she developed her passion for rare disease.
*Dr Workeneh is a paid consultant of Otsuka Pharmaceutical Development & Commercialization, Inc. (OPDC). Dr Jansen is an employee of OPDC.
Registration
Join Today for Instant Access to all NephU Offerings.
Membership is free!
Join NephU today at no cost to register for this event and access to other premium content.
- The NephU Community is collaborating to improve care and the future outcomes for individuals with kidney disease and other related conditions.
- Quickly learn more about the topics that interest you.
- Access our library of on-demand kidney health resources
- Gain key insights from industry experts & though leaders.
NephU is supported by Otsuka Pharmaceutical Development & Commercialization, Inc. (OPDC) and Otsuka America Pharmaceutical, Inc. (OAPI) - committed supporters of the Kidney Health Community. The information provided through NephU is intended for the educational benefit of health care professionals and others who support care for those with kidney disease and other related conditions. It is not intended as, nor is it a substitute for, medical care, advice, or professional diagnosis. Health care professionals should use their independent medical judgement when reviewing NephU’s educational resources. Users seeking medical advice should consult with a health care professional. No CME or CEU credits are available through any of the resources provided by NephU. Some of the contributors may be paid consultants of OPDC and/or OAPI.©2024 Otsuka Pharmaceutical Development & Commercialization, Inc. All rights reserved.